Lewis, F., Karlsberg Schaffer, S., Sussex, J., O'Neill, P. and Cockcroft, L.
Alzheimer’s Research UK commissioned OHE Consulting to model the incidence and cost of dementia in the UK and the potential impact of better treatment. The analyses estimate the extent of the substantial reductions in health and social care costs that are possible to 2050.
Karlsberg Schaffer, S., Sussex, J., Hughes, D. and Devlin, N.
This new research from the OHE examines how Local Health Boards (LHBs) in Wales adjust spending to meet the statutory requirement of providing access to technologies recommended by NICE within three months after NICE publishes a Technology Appraisal (TA). Based on interviews with medical and/or finance directors of the seven Wales LHBs, the study covers the period from October 2010 through March 2013.
Rejon-Parrilla, J.C., Hernandez-Villafuerte, K., Shah, K., Mestre-Ferrandiz, J., Garrison, L. and Towse, A.
This report examines the importance and history of HTA evaluations for additional uses for cancer drugs after their initial approval. Included are the ten cancer drugs approved by the EMA during 2003–2005. Decisions by France’s HAS, NICE and Aetna in the US are analysed.
Based on an OHE Lunchtime Seminar, this publication addresses a persistent issue: how to adequately reward innovation through the pricing of new medicines given the limitations of the information available at launch. As the author points out, oncology drugs in particular often follow the path of incremental innovation, proceeding in steps towards realising their full potential in treatment -- and even cure.
Mestre-Ferrandiz, J., Deverka, P., Pistollato, M. and Rosenberg, E.
The project reported in this Occasional Paper was intended to determine how changing demands for evidence are affecting drug development in five global pharmaceutical companies: Amgen, Eli Lilly, GSK, Novartis and Sanofi-Aventis. A literature review helped elucidate concepts and define focus. The authors then conducted semi-structured interviews with an international sample of 19 senior pharmaceutical executives in various positions in the five companies: R&D, outcomes research, medical affairs, and pricing and reimbursement.
This Briefing summarises the results of a roundtable convened by OHE to discuss using HTA to assess biosimilars – including which methods are most appropriate in specific situations. Participating were ten experts: leading academics and representatives from the UK medicines regulatory agency, the three UK HTA entities, and the UK industry trade association. Background for discussion at the meeting included an OHE literature review and ABPI’s 2013 position paper on biosimilar medicines.
Cost-effectiveness analysis plays a limited role in US health care compared to many other countries. In this Seminar Briefing, Dr James Chambers, Center for the Evaluation of Value and Risk in Health at Tufts Medical Center, considers the current use of cost-effectiveness analysis in the US and explores the potential value of including it in decisions about coverage for medical technology by Medicare (the national public health insurance programme primarily for people 65+ years of age).
This monograph, based on Professor Maynard’s remarks at the 20th OHE Annual Lecture, explores the critical issue of ensuring the quality of care in the NHS. The lecture was delivered just five months after release of the Francis Report, which was the result of a public inquiry into serious failures in patient care at the Mid Staffordshire NHS Foundation Trust. As with many such inquiries in the past, Francis’s recommendations envisioned more regulation.
O’Neill, P., Mestre-Ferrandiz, J., Puig-Peiro, R. and Sussex, J.
The Pharmaceutical Price Regulation Scheme (PPRS) 2014 Heads of Agreement, announced on 6 November 2013, outlines the terms of the five-year deal between the pharmaceuctical industry and the government in the UK. For the first time, the PPRS caps future growth in the NHS's branded medicines bill, between 2014 and 2018.
Karlsberg Schaffer, S., Sussex, J., Devlin, N. and Walker, A.
This research examines the use of QALY thresholds in NHS Scotland in 2012-13 for health services that were "at the margin", i.e. those for which investment or disinvestment was planned or occurred.
The study was based on information from three sources: public information from the Scottish Parliament's examination of the NHS Boards' expenditure plans, interviews with the Finance Directors of Scotland's territorial NHS Boards, and a literature review.